Home › Inflammatory Bowel Disease › Ohio
Inflammatory Bowel Disease clinical trials in Ohio
15 studies for Inflammatory Bowel Disease are looking for participants at sites in Ohio.
Cities in Ohio
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-025, Brunswick
- Site US-023, Dayton
- Site US-027, Westlake
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07845487Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
- Xencor Investigative Site, Beavercreek
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT06619990Non-nutritive Sweeteners in Inflammatory Bowel Disease
- UH Minoff Health Center, Chagrin Falls
- University Hospitals Cleveland Medical Center, Cleveland
- UH Westlake Health Center, Westlake
RecruitingHealthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Sep 25, 2026 · NCT07769437Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345Study of DISC-0974-201 in Participants With IBD and Anemia
- Gastro Health - Cincinnati, Cincinnati
- Gastro Health - Blue Ash Care Center, Cincinnati
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07368972Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
- Cleveland Clinic Foundation, Cleveland
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 21, 2026 · NCT07513181A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 4
3 Weeks · Women · Updated Sep 8, 2026 · NCT07612267A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Childrens Medical Center, Dayton
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Aug 24, 2026 · NCT05509777Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Cincinnati, Cincinnati
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07237516A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- GCGA Physicians, LLC dba / Gastro Health Research, Cincinnati
- NexGen Research, Lima
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jul 30, 2026 · NCT06598943Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Cincinnati Children's Hospital Medical Center, Cincinnati
- UH/Rainbow Babies and Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool
- Gastro Intestinal Research Institute of Northern Ohio,, Westlake
RecruitingObservational studyHealthy volunteers welcome
Ages 22 and older · All sexes · Updated Apr 28, 2026 · NCT06810518A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cincinnati
- Mirador Therapeutics Selected Site, Liberty Township
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522Evaluation of the SMART IBD App in Pediatric IBD
- Cincinnati Children's Hospital Medical Center, Cincinnati
Recruiting
Ages 13 to 17 · All sexes · Updated Nov 21, 2025 · NCT07195123Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- University of Cincinnati, Cincinnati
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 8, 2025 · NCT06750731From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.